Brand and Other Names:Prialt
- Classes: Analgesics, Other
Dosing & Uses
Dosage Forms & Strengths
2.4 mcg/day intrathecal (IT), (0.1 mcg/hour)
Titrate up by 2.4 mcg/day at intervals 2-3 times per week or less if necessary; no more than 19.2 mcg/day (0.8 mcg/hour) by Day 21
Use in only the Medtronic SynchroMed® EL or SynchroMed® II Infusion System or Simms Deltec Micro® External Microinfusion Device & Catheter
Medtronic Devices: Only the 25 mcg/mL undiluted solution is used for naive pump priming & initial pump fill
Simms Deltec Device: use 5 mcg/mL Prialt diluted in NS
See manufacturer's package inserts for details
Cognitive functions, mood alterations
Safety/efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Abnormal gait (14%)
Abnormal vision (12%)
Memory impairment (12%)
Frequency Not Defined
Black Box Warnings
Severe psychiatric symptoms and neurologic impairment may occur during treatment with ziconotide. Patients with a preexisting history of psychosis should not be treated with ziconotide.
All patients should be monitored frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Ziconotide therapy can be interrupted or discontinued abruptly without evidence of withdrawal effects in the event of serious neurologic or psychiatric signs or symptoms.
History of psychosis
IT administration to patients with uncontrolled bleeding, infection at the injection site, spinal obstruction that impairs CSF circulation
IT administration only
Possibility of severe psychiatric & neurological complications
- Risk of severe or worsening depression w/ suicide risk in susceptible pts
- Monitor for cognitive impairment, hallucinations & mood swings
- Can be interrupted or discontinued abruptly without withdrawal effects
Possibility of meningitis & other infections
Levels of serum creatinine kinase may increase
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Excretion into breast milk unknown; discontinue drug or do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Putative calcium channel blocker, synthetic conopeptide; binds to N-type voltage sensitive calcium channels located in nociceptive afferent nerves of the dorsal horn in the spinal cord
Not an opioid and does not bind to opioid receptors
Protein Bound: 50%
Vd: 140 mL
Metabolism: by peptidases outside of CSF
Metabolites: small peptides/amino acids
Half-life: 1-1.6hr in plasma (IV); 2.9-6.5hr in CSF (IT)
Excretion: Urine (<1%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs